Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer

New reliable biomarkers are needed to predict the response to immune checkpoint inhibitors against programmed death-1 (PD-1) and its ligand (PD-L1), because PD-L1 expression on tumor cells has limited power for selecting patients who may benefit from such therapy. Here we investigated the significan...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Inoue, Yusuke, Yoshimura, Katsuhiro, Mori, Kazutaka, Kurabe, Nobuya, Kahyo, Tomoaki, Mori, Hiroki, Kawase, Akikazu, Tanahashi, Masayuki, Ogawa, Hiroshi, Inui, Naoki, Funai, Kazuhito, Shinmura, Kazuya, Niwa, Hiroshi, Suda, Takafumi, Sugimura, Haruhiko
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2016
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5078001/
https://ncbi.nlm.nih.gov/pubmed/27050074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8528
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak